Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Dr. Kerklaan Therapeutics, The Premiere Doctor-Created and Tested CBD Wellness Line, Leads Industry Expansion Into Global Retailers


News provided by

Dr. Kerklaan Therapeutics

11 Nov, 2019, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

Dr. Kerklaan Therapeutics amongst the first CBD products to be on shelves at Selfridges, DFS North America, Dillard's and Lord + Taylor

LOS ANGELES, Nov. 8, 2019 /PRNewswire/ -- Dr. Kerklaan Therapeutics (DrKerklaan.com), the provider of premium CBD-based, natural topical products, today announced major global expansion, beginning with the UK's luxury department store Selfridges, duty free retail leader DFS North America, American retailers Dillard's and Lord + Taylor, as well as Goodleaf, the South African premium distributor of CBD.

Continue Reading
This image opens in the lightbox
Dr. Andrew Kerklaan- Founder, Dr. Kerklaan Therapeutics

As one of the only CBD brands on the market today fully formulated, developed, and tested by a doctor, Dr. Kerklaan Therapeutics has seen exponential sales growth in the last year. With this international expansion, Dr. Kerklaan Therapeutics will be  available to purchase in over 3,000 retail locations on four continents starting in 2020 and is forecasted to see growth of six times in revenue from 2019 to 2020. In addition, Dr. Kerklaan Therapeutics is one of the very few brands that is vertically integrated, and owns their own refinement facility to ensure the use of only the highest quality CBD oil in their products. 

While caring for thousands of patients in his clinical practice for nearly a quarter century, Montreal-based Dr. Andrew Kerklaan has spent his career focusing on health and wellness with the deeply-held philosophy that the best approach to optimum health is most often a natural, non-invasive one. This belief, along with his patients' search for natural solutions, inspired Dr. Kerklaan to explore the benefits of hemp-derived, CBD-based products. Dr. Kerklaan has become the "go-to" expert on the science and potential health benefits of CBD.

"I have been on the front lines of health and wellness for more than 20 years. I saw the struggle my patients endured while trying to find effective, natural ways to improve their health," says Dr. Andrew Kerklaan, DC, Founder and Creator of Dr. Kerklaan Therapeutics. "Using CBD topically offers enormous potential for people searching for natural, plant-based approaches to support their well-being. The fact that high-profile global retailers are introducing CBD as a product offering is an enormous step for our industry and significantly supports my mission to provide high quality, effective, and natural alternatives to consumers all over the world. This is just the beginning."

This fall, Dr. Kerklaan Therapeutics became available at select Dillard's and Lord + Taylor stores nationwide. Shoppers will be able to purchase a variety of the CBD leader's 100% US grown, full spectrum CBD topical products, including Relief, Sleep, PMS, and Skin at these stores. The offerings range in size from 1-2 oz., and are priced from $39.99 - $68.00.

Travelers passing through LAX, JFK and SFO airports can purchase Dr. Kerklaan Therapeutics products at the DFS North America stores.

In the UK, Dr. Kerklaan Therapeutics is proud to be one of the first CBD brands featured at legendary department store Selfridges. The retailer is featuring Dr. Kerklaan Therapeutics at top locations, including the flagship London Oxford Street, the beauty workshop concept at the Manchester Trafford store, and online at Selfridges.com.

Recently, Dr. Kerklaan Therapeutics announced a retail partnership with South Africa-based Goodleaf to sell products at their first brick and mortar store in the center of Cape Town.

In the US market alone, CBD product sales are expected to top $20 billion by 2024. Dr. Kerklaan Therapeutics is leading the way in the premium product space in global locations like Europe and South Africa, with imminent plans to expand into South America.

About Dr. Kerklaan Therapeutics
Dr. Kerklaan Therapeutics provides upscale, highly effective plant-based CBD topical solutions. Dr. Kerklaan's approach to designing CBD-infused health and wellness products blends modern biochemistry with time-tested cannabidiol-based remedies. Made with the highest quality ingredients, Dr. Kerklaan Therapeutics combines premium essential oils with prime Oregon-grown hemp extracts. All of Dr. Kerklaan Therapeutics products are rigorously tested by top licensed, independent third party labs for quality and CBD concentration certification and are made to the highest standards of safety and efficacy. Learn more at DrKerklaan.com

Media Contacts


Hustle&Co.

Dr. Kerklaan Therapeutics

Jenn DeMartino Callister

Jennifer Miller

drkerklaanpr@feelthehustle.com  

jenniferm@drkerklaan.com

Photo - https://mma.prnewswire.com/media/1025935/Dr_Kerklaan_Therapeutics.jpg

Related Links

http://drkerklaan.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.